Antiretrovirals – PharmaLive

U.S. FDA Approves Streamlined Process for Initiating HIV Therapy with Cabenuva

Antiretrovirals, FDA/Regulatory, HIV-1, Injectables, Integrase strand transfer inhibitors, Janssen, Labeling Update, Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), Therapeutics, ViiV Healthcare

ViiV Healthcare and Janssen Pharmaceutical’s Cabenuva treatment for people living with human immunodeficiency virus (HIV-1) received a label update as adult patients now have the option to start the injectable regimen without the need for an oral lead-in period first.

March 25, 2022/by BioSpace

GSK to get $1.25 billion to settle HIV drug patent row with Gilead

Antiretrovirals, Blockbusters, Business, Gilead, GlaxoSmithKline, HIV, Injectables, Legal, Patent Disputes, Patents, Royalties, Settlements, Settlements, Therapeutics, ViiV Healthcare

Britain’s GlaxoSmithKline will receive $1.25 billion from Gilead Sciences as part of a settlement between GSK’s HIV medicines unit and the U.S.-based drugmaker, ending a long-drawn patent dispute.

February 2, 2022/by Reuters Health

New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead’s Investigational HIV-1 Capsid Inhibitor

Antiretrovirals, Capsid inhibitors, Clinical Data, Clinical Trials, Gilead, HIV infections, Multi-drug resistant HIV-1 infection, R&D

Gilead Sciences Inc. announced new results from the Phase 2/3 CAPELLA trial evaluating lenacapavir, the company’s investigational, long-acting HIV-1 capsid inhibitor, in heavily treatment-experienced people living with multi-drug resistant HIV.

July 17, 2021/by Andrew Humphreys

FDA approves ViiV’s Cabenuva as first complete long-acting regimen for HIV treatment

Adults, Antiretrovirals, Approvals, Clinical Trials, FDA, First-In-Class, GlaxoSmithKline, HIV-1, New Drug Applications, Patient Assistance Programs, R&D, Therapeutics

The U.S. Food and Drug Administration approved ViiV Healthcare’s Cabenuva as the only complete long-acting regimen for the treatment of HIV-1 infection in adults.

January 21, 2021/by Andrew Humphreys

As Death Toll Climbs, WHO Finds No Benefit with 4 Top Covid-19 Treatments

Antiretrovirals, Biopharma Companies, Clinical Trials, Coronavirus Disease (COVID-19) Pandemic, Hospitalized COVID-19 Patients, Hydroxychloroquine, Interferon-beta-1a, Lopinavir, Mortality Rates, New England Journal of Medicine, R&D, Remdesivir, World Health Organization

Once touted as promising treatments and by some even a cure, the World Health Organization dashes those claims, finding no benefit in the use of four popular Covid-19 treatments (remdesivir, hydroxychloroquine, lopinavir, or interferon-beta-1a) on hospitalized patients.

December 4, 2020/by Reuters Health